<code id='B6B366078D'></code><style id='B6B366078D'></style>
      • <acronym id='B6B366078D'></acronym>
      <center id='B6B366078D'><center id='B6B366078D'><tfoot id='B6B366078D'></tfoot></center><abbr id='B6B366078D'><dir id='B6B366078D'><tfoot id='B6B366078D'></tfoot><noframes id='B6B366078D'>
      • <optgroup id='B6B366078D'><strike id='B6B366078D'><sup id='B6B366078D'></sup></strike><code id='B6B366078D'></code></optgroup>
        5. <b id='B6B366078D'><label id='B6B366078D'><select id='B6B366078D'><dt id='B6B366078D'><span id='B6B366078D'></span></dt></select></label></b><u id='B6B366078D'></u>
          <i id='B6B366078D'><strike id='B6B366078D'><tt id='B6B366078D'><pre id='B6B366078D'></pre></tt></strike></i>
           


   

   

   
   
   
   
   
   
   
   
   
   
   
   
   

   
   
   
   
   
   
   
  
           
  
           
  
           
   
           
    
           
     
           
      
           
       
      
           
      
           
       
           
        
           
         
           
           
          
           
         
           
         
           
           
          
           
         
           
          
        
           
       
           
       
           
        
           
        
           
        
           
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
       
           
       
           
        
           
        
          
          00:00 
        
           
       
           
       
           
      
           
      
           
        
        
        
       
           
        00:00 
         
        00:00 
        LIVE 
       
           
        
       
           
        
           
        
           
        
           
        
           
       
           
       
           
       
           
        
        
        
        
        
        
        
        
        
      
           
       
    
    
      
           
       
           
      
           
     
           
     
           
       
     
           
     
           
      
           
      
           
      
           
      
           
       
           
      
           
      
           
      
           
       
           
       
          
         buffering 
       
           
      
           
      
           
       
           
        
           
        
          
          Replay 
        
           
       
           
      
           
       
      
           
      
           
       
           
       
           
        
           
        
           
        
           
       
           
      
           
      
           
      
           
      
           
      
           
       
           
      
           
     
           
     
           
      
           
     
           
     
           
      
           
       
           
        
           
       
           
       
           
        
          
          LIVE 
        
           
        00:00 
         /  
        00:00 
       
           
       
           
        
           
        
           
        
           
         
           
         
           
         
           
         
           
         
           
         
           
        
           
        
           
        
           
       
           
       
           
        
           
        
          
          LIVE 
        
           
       
           
       
           
        
           
        
          
          CC 
        
           
       
           
       
           
        
           
       
           
       
           
       
           
        
           
        
           
         
           
        
           
       
           
       
           
        
           
       
           
      
           
      
           
       
           
        
           
        
           
         
           
         
           
         
           
          
           
          
           
          
           
         
           
        
           
       
           
      
           
      
           
       
           
     
       
           
    
       
           
       
    
  
       
           
   
       
           
       
       
           
      
           
      
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       
           
       Opacity : 
        
      
           
     
           
     
           
     
           
      
           
  
     
           
    
           
    
           
    
           
     
          
       Share: 
     
           
      
     
           
      
      Copy 
     
           
      
    
           
    
          
      Close 
      
    
           
    
           
      
    
           
    
           
   
           
  
           
  
           
    
    
    
   
           
   
           
 
    
   
           
   
           
   
           
    
           
     
           
      
           
       
           
        
           
          
          
         
          
          explore 

          
          
            
          
          

           
           
        
           
       
           
      
           
     
           
    
           
    
           
     
           
      
           
      
           

                       
          hotspot  
          
                                   
                 
                                      author：Wikipedia   
                                        
                                      
                                      -
 
browse：464
                                  
                                    
          
                                    
            
          
 
          David Liu
          Beam Therapeutics co-founder David Liu																									Courtesy Stephanie Mitchell/Harvard
          Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.
          It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.
          advertisement
          Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe													Log In											
           
 
 
          

                              
          
                                 Previous article：

                                
                                          State Dept. review finds Biden bears some blame for Afghanistan failures
                                
                            
          Next article：  
                                      
                                          A rare thyroid diagnosis led to unexpected, all
                                                                    
          

      
           
      
           
        
           
                                               
        
           explore 
           
                   
      
           
  
  
          
    
          
        
          
            
          
                                                     
                
          hotspot
          
                            
          
        
          
        
    
          

          

    

      
           
     
           


   
    
           
   
           
  
 

  
           
    
           
           
           
            
            Back To Top 
           
           
           
           

            
           
                                                                    
                 
          focus
           
                                      
            
           
          
           
                                                          
             
          Wikipedia
           
                             
            
           
            
           

                                                         
             
          hotspot
           
               
              
            
           
            
           
                                                         
             
          focus
           
                             
      
           
 
     
           
     
           
      
          
              DrewAngerer/GettyImagesTheU.S.SupremeCourt’sdecisiontoconsiderthelegalityofIdaho’sabortionlaw—andtor
             
           
      
          
        © 2013-2023.Company name All rights reserved.Site Map 
         WSS-More Templates  
             Guangdong ICP22name